Clinical Features and Pathogenesis of Migraine
Migraine is a chronic disorder manifesting as recurrent attacks of debilitating headache. The pain is typically unilateral and characterized by a pronounced throbbing quality. Without pharmacological intervention, a single attack lasts anywhere from 4 to 72 hours. The condition can affect patients for many years, with an average frequency ranging from one to four attacks per month.
In addition to the headache itself, the clinical picture is often complicated by associated symptoms, including severe nausea progressing to vomiting, as well as visual and auditory disturbances.
The exact etiology and pathogenesis are not fully elucidated; however, the leading medical theory links migraine development to impaired regulation of cerebral vascular tone. Furthermore, the critical role of the serotonergic system in the pathophysiology of this condition has been definitively confirmed.
Classification of Drugs for Acute Attack Abortive Therapy
The pharmacotherapeutic strategy for migraine is clearly divided into acute attack management and prevention of future episodes. Two main classes of medications are used for rapid pain relief in modern practice.
The first class consists of nonspecific analgesics, which provide general pain relief. This category includes:
- Non-opioid analgesics (represented primarily by paracetamol).
- Nonsteroidal anti-inflammatory drugs, or NSAIDs (most commonly acetylsalicylic acid and ibuprofen).
The second class comprises specific agents that directly affect cerebral circulation. Their mechanism of action is based on the stimulation of serotonin receptors (specifically the 5-HT1D subtype). These include:
- Serotonin receptor agonists (triptans). The primary agent in this group is sumatriptan. Its pathogenetic mechanism for pain relief involves reducing the excessive cerebral vasodilation and pulsation that trigger the migraine headache.
- Ergot alkaloids. These include ergotamine and its dihydrogenated derivatives. A notable feature is their route of administration; for instance, dihydroergotamine is frequently utilized as a nasal spray, ensuring convenient use during an acute attack.
Symptomatic Therapy and Prophylaxis During the Interictal Period
Acute migraine management extends beyond pain control. To manage associated gastrointestinal symptoms, particularly vomiting, antiemetics are utilized. The primary drug of choice in this setting is metoclopramide.
When attacks occur frequently, prophylactic therapy is indicated. This is administered strictly during the interictal (between-attack) period. The primary goal of prophylactic treatment is to significantly reduce the frequency and severity of future attacks. Agents from diverse pharmacological classes are used for prophylaxis:
- Serotonin receptor antagonists (blocking 5-HT2 receptors): methysergide.
- Beta-blockers: propranolol.
- Tricyclic antidepressants: amitriptyline.
- Anticonvulsants: carbamazepine and clonazepam.